Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma



Status:Active, not recruiting
Healthy:No
Age Range:18 - Any
Updated:8/19/2018
Start Date:May 2014
End Date:June 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The objective of this study is to investigate the utility of 99mTc-sestamibi SPECT/CT imaging
for the diagnosis of renal oncocytomas.


Inclusion Criteria:

- Presence of a solid enhancing cT1 renal mass detected on cross-sectional imaging

- Scheduled to undergo surgery with either partial or radical nephrectomy

- Age ≥18 years

Exclusion Criteria:

- Pregnancy

- Evidence of nodal or distant metastases

- History of other malignancy with concern for renal metastasis

- Known allergy to technetium or sestamibi
We found this trial at
1
site
Johns Hopkins Hospital
1800 Orleans St.
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Mohamad E. Allaf, M.D.
Phone: 410-614-8151
Johns Hopkins Hospital Patients are the focus of everything we do at The Johns Hopkins...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials